ES2665851T3 - Nuevo anticuerpo anti-CTGF humano - Google Patents
Nuevo anticuerpo anti-CTGF humano Download PDFInfo
- Publication number
- ES2665851T3 ES2665851T3 ES12860742.1T ES12860742T ES2665851T3 ES 2665851 T3 ES2665851 T3 ES 2665851T3 ES 12860742 T ES12860742 T ES 12860742T ES 2665851 T3 ES2665851 T3 ES 2665851T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- ctgf
- human
- human anti
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011281811 | 2011-12-22 | ||
| JP2011281811 | 2011-12-22 | ||
| PCT/JP2012/083206 WO2013094723A1 (ja) | 2011-12-22 | 2012-12-21 | 新規抗ヒトｃｔｇｆ抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2665851T3 true ES2665851T3 (es) | 2018-04-27 |
Family
ID=48668601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12860742.1T Active ES2665851T3 (es) | 2011-12-22 | 2012-12-21 | Nuevo anticuerpo anti-CTGF humano |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9587015B2 (https=) |
| EP (1) | EP2796550B1 (https=) |
| JP (1) | JP6040943B2 (https=) |
| KR (1) | KR20140107507A (https=) |
| CN (1) | CN104011206B (https=) |
| AR (1) | AR089425A1 (https=) |
| BR (1) | BR112014015405A2 (https=) |
| CA (1) | CA2859627A1 (https=) |
| EA (1) | EA029290B1 (https=) |
| ES (1) | ES2665851T3 (https=) |
| IN (1) | IN2014CN04615A (https=) |
| MX (1) | MX345019B (https=) |
| PL (1) | PL2796550T3 (https=) |
| PT (1) | PT2796550T (https=) |
| TW (1) | TW201333034A (https=) |
| WO (1) | WO2013094723A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109824777A (zh) * | 2019-03-15 | 2019-05-31 | 辽宁何氏医学院 | 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用 |
| US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
| CN115925926A (zh) * | 2019-06-04 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 抗结缔组织生长因子抗体及其应用 |
| CN116391041A (zh) * | 2020-12-03 | 2023-07-04 | 江苏恒瑞医药股份有限公司 | 一种含抗结缔组织生长因子抗体的药物组合物 |
| JPWO2023238845A1 (https=) | 2022-06-07 | 2023-12-14 | ||
| TW202434302A (zh) | 2022-10-31 | 2024-09-01 | 日商安斯泰來製藥股份有限公司 | 包含類鐸受體７／８雙重促效劑化合物之抗體藥物複合體 |
| TW202502816A (zh) * | 2023-03-10 | 2025-01-16 | 大陸商上海濟煜醫藥科技有限公司 | 一種靶向ｃｔｇｆ的抗體或其抗原結合片段及其應用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8808645U1 (de) | 1988-07-06 | 1988-08-25 | Hofer, Daniel, 7730 Villingen-Schwenningen | Anzeigeeinrichtung für Feuerlöscher |
| WO1994020632A1 (fr) | 1993-03-11 | 1994-09-15 | Juridical Foundation The Chemo-Sero-Therapeutic R Esearch Insitute | Anticorps monoclonal dirige contre le vih |
| JP4537507B2 (ja) | 1997-12-25 | 2010-09-01 | アムジェン インコーポレイテッド | 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途 |
| WO1999033878A1 (en) * | 1997-12-25 | 1999-07-08 | Japan Tobacco Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
| US7115390B1 (en) | 1998-12-14 | 2006-10-03 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| DK1140969T3 (da) | 1998-12-14 | 2007-09-17 | Univ Miami | Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| JP2009067678A (ja) * | 2005-12-07 | 2009-04-02 | Nihon Nosan Kogyo Kk | 結合組織増殖因子に対する抗体又はそれを含む組成物 |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
-
2012
- 2012-12-21 MX MX2014007681A patent/MX345019B/es active IP Right Grant
- 2012-12-21 IN IN4615CHN2014 patent/IN2014CN04615A/en unknown
- 2012-12-21 EA EA201491240A patent/EA029290B1/ru not_active IP Right Cessation
- 2012-12-21 KR KR1020147020039A patent/KR20140107507A/ko not_active Abandoned
- 2012-12-21 WO PCT/JP2012/083206 patent/WO2013094723A1/ja not_active Ceased
- 2012-12-21 CN CN201280063995.5A patent/CN104011206B/zh not_active Expired - Fee Related
- 2012-12-21 AR ARP120104933A patent/AR089425A1/es unknown
- 2012-12-21 US US14/367,081 patent/US9587015B2/en not_active Expired - Fee Related
- 2012-12-21 PL PL12860742T patent/PL2796550T3/pl unknown
- 2012-12-21 PT PT128607421T patent/PT2796550T/pt unknown
- 2012-12-21 JP JP2013550349A patent/JP6040943B2/ja not_active Expired - Fee Related
- 2012-12-21 EP EP12860742.1A patent/EP2796550B1/en active Active
- 2012-12-21 BR BR112014015405A patent/BR112014015405A2/pt unknown
- 2012-12-21 ES ES12860742.1T patent/ES2665851T3/es active Active
- 2012-12-21 CA CA2859627A patent/CA2859627A1/en not_active Abandoned
- 2012-12-21 TW TW101148989A patent/TW201333034A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2796550B1 (en) | 2018-02-28 |
| EP2796550A1 (en) | 2014-10-29 |
| EA029290B1 (ru) | 2018-03-30 |
| JPWO2013094723A1 (ja) | 2015-04-27 |
| BR112014015405A2 (pt) | 2017-06-13 |
| KR20140107507A (ko) | 2014-09-04 |
| PT2796550T (pt) | 2018-04-18 |
| MX2014007681A (es) | 2014-11-25 |
| AR089425A1 (es) | 2014-08-20 |
| EA201491240A1 (ru) | 2014-11-28 |
| EP2796550A4 (en) | 2015-08-19 |
| US9587015B2 (en) | 2017-03-07 |
| TW201333034A (zh) | 2013-08-16 |
| MX345019B (es) | 2017-01-11 |
| CN104011206B (zh) | 2017-03-08 |
| JP6040943B2 (ja) | 2016-12-07 |
| CN104011206A (zh) | 2014-08-27 |
| WO2013094723A1 (ja) | 2013-06-27 |
| IN2014CN04615A (https=) | 2015-09-18 |
| CA2859627A1 (en) | 2013-06-27 |
| US20140343258A1 (en) | 2014-11-20 |
| PL2796550T3 (pl) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7538721B2 (ja) | 抗インターロイキン１７ａ抗体、医薬組成物、およびその使用 | |
| ES2444012T3 (es) | Composiciones y metodos relacionados con anticuerpos de receptores de glucagón | |
| ES2581229T3 (es) | Proteínas de unión a antígeno capaces de unirse a linfopoyetina estromal tímica | |
| ES2813432T3 (es) | Proteínas y péptidos modificados | |
| ES2655912T3 (es) | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos | |
| ES2536228T3 (es) | Anticuerpos antagonistas de IL-17 | |
| ES2665851T3 (es) | Nuevo anticuerpo anti-CTGF humano | |
| BR112021001201A2 (pt) | anticorpo anti-tigit e uso do mesmo | |
| KR101999867B1 (ko) | 신규 항 인간 ngf 항체 | |
| PT1248804E (pt) | Anticorpos contra il-1b humana | |
| JP6865826B2 (ja) | インターロイキン１７ａを標的とする抗体、その製造方法及び応用 | |
| JP2026053563A (ja) | 補体関連疾患のための融合タンパク質構築物 | |
| ES2728438T3 (es) | Anticuerpo anti-receptor de IL-23 humano nuevo | |
| TWI843763B (zh) | 抗人類Fn14抗體 | |
| ES2903412T3 (es) | Anticuerpos anti-IL-22R | |
| JP2021533770A (ja) | 抗ＩＬ−１β抗体およびその医薬組成物およびそれらの使用 | |
| CN112079925A (zh) | 靶向lag-3的抗体和双特异性抗体及其用途 | |
| ES2701064T3 (es) | Novedoso anticuerpo antirreceptor IL-23 humano | |
| ES2726915T3 (es) | Nuevo anticuerpo anti-PAI-1 humano | |
| ES2709996T3 (es) | Nuevo anticuerpo biespecífico que se une al TLR2 humano y al TLR4 humano | |
| US11976115B2 (en) | Antibody binding to human IL-1β, preparation method therefor and use thereof | |
| TW202325739A (zh) | 新穎Nav1.7單株抗體 | |
| RU2787044C2 (ru) | АНТИТЕЛО ПРОТИВ Fn14 ЧЕЛОВЕКА | |
| WO2024002145A1 (zh) | 结合il-17a和il-17f的抗体分子及其应用 | |
| WO2026062389A1 (en) | Single domain antibodies against beta coronavirus spike protein s2 domain |